(Q34652719)

3 August 2017

title

Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia (English)

1 reference

3 August 2017

0 references

1 reference

1

Gillian M Keating

1 reference

3 August 2017

publication date

1 June 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

27

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

479-489

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-013-0075-9

3 August 2017

exact match

0 references

cites work

The expert consensus guideline series. Treatment of behavioral emergencies 2005.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

An investigation into the morphology of loxapine in a thermal aerosolization process from crystalline to amorphous

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

In vitro aerosol deposition in the oropharyngeal region for Staccato loxapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Contrasting loxapine to its isomer isoloxapine--the critical role of in vivo D2 blockade in determining atypicality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

3H-spiroperidol binding to dopamine receptors in rat striatal membranes: Influence of loxapine and its hydroxylated metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Now take a deep breath: inhaled loxapine for the treatment of acute agitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0075-9

Does loxapine have "atypical" properties? Clinical evidence

21 January 2018

1 reference

12 December 2020

In vitro aerosol characterization of Staccato(®) Loxapine

1 reference

12 December 2020

The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs

1 reference

12 December 2020

A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes

1 reference

12 December 2020

Loxapine P-glycoprotein interactions in vitro

1 reference

12 December 2020

Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine

1 reference

12 December 2020

Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors

1 reference

12 December 2020

Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia

1 reference

12 December 2020

Loxapine for schizophrenia

1 reference

12 December 2020

Clinical perspectives on atypical antipsychotics for treatment of agitation

1 reference

12 December 2020

A review of agitation in mental illness: treatment guidelines and current therapies.

1 reference

12 December 2020

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

A review of agitation in mental illness: burden of illness and underlying pathology.

1 reference

12 December 2020

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine

1 reference

12 December 2020

10.1007/S40263-013-0075-9

Identifiers

DOI

1 reference

3 August 2017

1 reference